Who can take part?
Patients with breast cancer which is HER2-positive type that has progressed, or spread, to other areas around the breast (locally advanced) or to other parts of your body (metastatic).
What is involved for you?
The trial goes for 52 weeks during which you will see your doctor and research coordinator approximately every three weeks for physical exams, ECG's blood tests, tumour assessments (ie-CT scans) and heart function tests. You will receive medicine injected into your veins every 3-4 weeks.